Diphenhydramine has similar interspecies net active influx at the blood-brain barrier

Journal of Pharmaceutical Sciences

Volumn 103, Issue 5, 2014, Pages 1557-1562

  Shaffer, Christopher L ^a   Osgood, Sarah M ^a   Mancuso, Jessica Y ^a   Doran, Angela C ^a  

^a PFIZER INC   (United States)

Author keywords

blood brain barrier; CNS; diphenhydramine; drug disposition; drug transport; preclinical pharmacokinetics

Indexed keywords

DIPHENHYDRAMINE; OXYCODONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BEAGLE; BLOOD BRAIN BARRIER; BODY SIZE; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TRANSPORT; FEMALE; FORECASTING; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; MEMBRANE TRANSPORT; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; RAT; SPECIES COMPARISON; STEADY STATE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BRAIN; DOG; EXTRACELLULAR FLUID; METABOLISM; MICRODIALYSIS; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DIPHENHYDRAMINE; DOGS; EXTRACELLULAR FLUID; FEMALE; MACACA FASCICULARIS; MALE; MICRODIALYSIS; OXYCODONE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84897996676     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23927     Document Type: Article

References (25)

1. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M,. 2009. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37: 787-793.
2. Weber ML, Hofland CM, Shaffer CL, Flik G, Cremers T, Hurst RS, Rollema H,. 2013. Therapeutic doses of antidepressants are projected not to inhibit human α4β2 nicotinic acetylcholine receptors. Neuropharmacology 72: 88-95.
3. Shaffer CL., 2010. Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-species pharmacologic exposure-response relationships. Annu Rep Med Chem 45: 55-70.
4. Hammarlund-Udenaes M., 2009. Active-site concentrations of chemicals-Are they a better predictor of effect than plasma/organ/tissue concentrations ? Basic Clin Pharmacol Toxicol 106: 215-220.
5. Doran AC, Osgood SM, Mancuso JY, Shaffer CL,. 2012. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab Dispos 40: 2162-2173.
6. Bostrom E, Simonsson USH, Hammarlund-Udenaes M,. 2006. In vivo blood-brain barrier transport of oxycodone in the rat: Indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos 34: 1624-1631.
7. Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, Jansson B, Bjorkman S, Terasaki T, Hammarlund-Udenaes M,. 2011. Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. J Pharm Sci 100: 3912-3923.
8. Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y,. 2008. Involvement of pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos 36: 2005-2013.
9. 1-anatgonist at the blood-brain barrier: Transport mechanism of mepyramine using the carotid injection technique. Biol Pharm Bull 17: 676-679.
10. 1-antagonist at the blood-brain barrier: Mepyramine uptake into the bovine brain capillary endothelial cells in primary monolayer cultures. Pharm Res 11: 975-978.
11. +/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model. Fluids Barriers CNS 10: 8.
12. Au-Yeung SCS, Rurak DW, Gruber N, Riggs KW,. 2006. A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: Potential involvement of a carrier-mediated mechanism. Drug Metab Dispos 34: 955-960.
13. Syvanen S, Lindhe O, Palner M, Kornum BR, Rahman O, Langstrom B, Knudsen GM, Hammarlund-Udenaes M,. 2009. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37: 635-643.
14. Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, Yang E, Serabjit-Singh CJ, Adkison KK, Polli JW,. 2004. Steady-state brain concentrations of anithistamines in rats. Pharmacology 72: 92-98.
15. Goldberg MJ, Spector R, Chiang C-K,. 1987. Transport of diphenhydramine in the central nervous system. J Pharmacol Exp Ther 240: 717-722.
16. 1-antagonists and lipophilic basic drugs. Pharm Res 11: 1516-1518.
17. Glazko AJ, Dill WA,. 1949. Biochemical studies on diphenhydramine (benadryl). II. Distribution in tissues and urinary excretion. J Biol Chem 179: 403-408.
18. 1-receptor antagonist with negligible ability to penetrate, the central nervous system. Br J Pharmacol 87: 569-578.
19. Friden M, Ljungqvist H, Middleton B, Bredberg U, Hammarlund-Udenaes M,. 2010. Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metabol 30: 150-161.
20. Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, Liston TE,. 2011. Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos 39: 1270-1277.
21. Shen DD, Artru AA, Adkison KK,. 2004. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56: 1825-1857.
22. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A,. 2008. On the rate and extent of drug delivery to the brain. Pharm Res 25: 1737-1750.
23. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J,. 2006. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34: 1443-1447.
24. de Roos AM, Rekker RF, Nauta WT,. 1970. The base strength of substituted 2-(diphenylmethoxy)-N,N-dimethylamines. Arzneim-Forsch 11: 1763-1765.
25. Tien J-H., 1990. Transdermal-controlled administration of oxycodone. J Pharm Sci 80: 741-743.